Tag: clinical trials
-
![Optimi Health (OPTI.C) transforming psychedelic treatment and wellness]()
Optimi Health (OPTI.C) transforming psychedelic treatment and wellness
In Canada, the prevalence of depression and mental health disorders has shown a worrying increase. According to data from 2022, over 5 million Canadians, accounting for 18% of the population aged 15 and older. This growing trend underscores the importance of addressing mental health issues at a societal and policy level, with an emphasis on…
-
![Perimeter Medical Imaging AI (PINK.V) Changing the Outcomes of Breast Cancer Surgery]()
Perimeter Medical Imaging AI (PINK.V) Changing the Outcomes of Breast Cancer Surgery
Breast cancer is the most diagnosed cancer among Canadian women and is the 2nd leading cause of cancer death. One in eight Canadian women can expect to receive a breast cancer diagnosis during their lifetime with a 19% chance of dying from the disease. Breast cancer surgery is often required, and patient outcomes are heavily…
-
![Today’s Idea: Filament Health (FH.NE) Gaining Traction]()
Today’s Idea: Filament Health (FH.NE) Gaining Traction
Problematic Psychedelics? Psychedelics and mental health treatment go together like orange juice and toothpaste. That’s what I would have said five years ago. Prior to the publication of multiple peer-reviewed studies, I adamantly believed psychedelics would melt your brain. In retrospect, that belief is just about as bogus as going to hell for premarital hand-holding.…
-
![Filament Health (FH.NEO) is doing the work to stand out in the psychedelics sector]()
Filament Health (FH.NEO) is doing the work to stand out in the psychedelics sector
I’ll admit that I’m beginning to have my suspicions about the psychedelic sector. The question I’ve started asking when I look at a new psychedelics company is where’s the evidence that they’re actually serious about getting products on shelves? How many startup drug companies at will never see the inside of a laboratory? Why? The…
-
![Filament Health (FH.NEO) brings an all natural option to fight depression and anxiety]()
Filament Health (FH.NEO) brings an all natural option to fight depression and anxiety
You’d be hard pressed to find someone who hasn’t been touched by depression or anxiety. Biochemically, they’re considered co-morbid, which means they often happen at the same time and feed off of one another. Depression and anxiety often overlap in terms of neurotransmitters and therefore, they’re often lumped together and treated the same way. And…
-
![Revive Therapeutics (RVV.C) incredible patent-portfolio explained]()
Revive Therapeutics (RVV.C) incredible patent-portfolio explained
Revive Therapeutics (RVV.C) is a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders. RVV holds 13 patents (issued and provisional) for covid-treatment, gout, drug delivery systems, cannabidiol and psilocybin. “We are proud of the IP portfolio that we’ve generated,” stated Michael Frank, CEO of Revive…
-
![Revive Therapeutics (RVV.C) latest spate of Bucillamine research could slow COVID-19 infection rates]()
Revive Therapeutics (RVV.C) latest spate of Bucillamine research could slow COVID-19 infection rates
Revive Therapeutics (RVV.C) signed a research agreement with the University of California, San Francisco (UCSF) to explore Bucillamine as a potential treatment for severe cases of COVID-19 today, according to a press release. The research will be done by Dr. John Fahy with the intention of testing the efficacy of Bucillamine in pre-clinical models of…
-
Revive Therapeutics (RVV.C) files for FDA Orphan Drug Designation for psilocybin in traumatic brain injury
“Psilocybin offers a potential solution to manage moderate to severe cases of TBI,” stated RVV, “Psilocybin has the potential with its neuroreparative effect to improve loss of cognitive function after TBI lessening disability”.
-
Ortho Regenerative (ORTH.C) targets Q2, 2021 FDA clinical trials to improve surgical outcomes for soft tissue repairs
“2021 will be transformational for the company as we advance the clinical development of our lead product,” added LeDuc.
-
![Revive Therapeutics (RVV.C) finds $23 million and throws it at their bucillamine clinical studies]()
Revive Therapeutics (RVV.C) finds $23 million and throws it at their bucillamine clinical studies
Revive Therapeutics (RVV.C) provided an update on their Phase 3 clinical trial for bucillamine for COVID-19 today. Primarily, the update’s about funding and more specifically their recent $23 million financing. The company intends to use the monies to fund their aggressive expansion from14 clinical sites to 50 to meet their enrolment requires for the study…
